Loading organizations...
§ Private Profile · Thousand Oaks, CA, USA
Clinical-stage biotechnology company developing targeted therapeutics for cancers using T-HDC technology, focused on HER2-negative breast cancer.
Dantari is a clinical-stage biotechnology company developing targeted therapeutics for oncology and other serious diseases, based in Thousand Oaks, California. The enterprise utilizes its Targeted High-capacity Drug Conjugate technology, originally developed at Caltech, to achieve higher drug-to-antibody ratios and tunable payload release compared to traditional antibody-drug conjugates. Its lead clinical candidate, DAN-222, is undergoing Phase 1/2 trials for the treatment of metastatic HER2-negative breast cancer, while a second candidate, DAN-311, is advancing toward human testing. The company emerged from stealth in late 2022 after securing $47 million in Series A funding backed by Westlake Village BioPartners, Corner Ventures, and Alexandria Venture Investments. Operating with a portfolio of two filed patents, the firm focuses on advancing its clinical pipeline to address unmet medical needs across the healthcare industry. Dantari was founded in 2018 by Richard A. Markus.
Dantari has raised $47.0M across 1 funding round.
Dantari has raised $47.0M in total across 1 funding round.
Dantari has raised $47.0M in total across 1 funding round.
Dantari's investors include Sean E. Harper, Alexandria Venture Investments, California Institute of Technology, Corner Ventures.
Dantari has raised $47.0M across 1 funding round. Most recently, it raised $47.0M Series A in December 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 8, 2022 | $47M Series A | Sean E. Harper | Alexandria Venture Investments, California Institute OF Technology, Corner Ventures | Announced |